To compare findings in a hospital trial of hypotensive drugs with those in a general practice trial several patients with mild hypertension were studied at the same time in hospital and in general practice. They received bendrofluazide and potassium chloride or bendrofluazide, potassium chloride, and reserpine according to a double-blind crossover protocol, and blood biochemical values were studied over eight weeks and six months. When reserpine was withdrawn from nine women they followed a modified protocol comparing bendrofluazide and potassium chloride with potassium chloride alone.
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Introduction
Clinical trials of antihypertensive drugs are usually carried out in hospitals, where strict control of conditions can be ensured. Difficulty in recruiting enough patients in hospital and a feeling that less artificiality attaches to studies conducted away from the wards or outpatient clinics have led recently to many more trials being performed exclusively in general practice.1 2 So far as we know no comparison has ever been made of results obtained in the same patient population studied at the same time both in general practice and the hospital clinic. This doubleblind crossover study was designed to provide such a comparison using well-established treatment for mild hypertension.
In most clinical trials short-term changes in the patients' blood chemistry are reported, from which long-term conclusions are sometimes drawn. As a secondary objective in this study we have examined and compared the changes in chemical values in the plasma (including plasma renin activity (PRA) ) over both short (eight weeks) and longer periods (six months) of treatment. When the initial 24 weeks of the trial were over the code was broken and each patient received the treatment giving the more satisfactory control. Monthly visits to the general practitioner were made before the patient returned to hospital one year from the start of the trial.
When the safety of reserpine came into question4-6 during the trial the protocol was modified so that women no longer received this compound. The modification gave rise to a subgroup of nine patients in whom bendrofluazide with potassium chloride was compared with potassium chloride alone.
Results
Of the 33 patients admitted to the trial 24 (10 women and 14 men) followed the original protocol and nine (all women) followed the modified protocol excluding reserpine. Twenty-six patients completed the first six months of the trial (19 on original protocol; 7 on modified protocol). One patient was withdrawn because the diastolic blood pressure rose above 120 mm Hg soon after the beginning of treatment. One patient moved away and two others failed to attend for follow-up. Three patients were withdrawn because of unwanted side effects. The total number of attendances required of each patient during the first 24 weeks of the study was Long-term-Eighteen patients continued to take bendrofluazide and potassium from weeks 24 to 52 of the trial, including 9 women in whom reserpine had to be avoided. Mean blood pressures remained significantly lower than control values after one year's treatment but were not significantly different from those measured at 24 weeks. The same conclusion was drawn from the results in six patients who received reserpine and the diuretic from weeks 24 to 52.
BIOCHEMISTRY
No significant changes in fasting blood cholesterol, calcium, or glucose concentrations were found after treatment with bendrofluazide with or without reserpine, either in the short term (8 weeks) or after six months' continuous treatment.
Both the mean fasting blood urea and urate concentrations, although remaining within the normal range, were significantly higher in the short-term (8 weeks) period on bendrofluazide regardless of the presence of reserpine. Over the next six months they remained significantly raised only in those patients receiving the diuretic and potassium chloride tablet alone (see table) .
The mean plasma potassium concentration remained within normal limits at all stages of the study although there was a significant lowering with both treatments in the short term. In the long term the plasma potassium concentration returned to pretreatment levels in the five patients who received reserpine as well as the diuretic (see table) .
PLASMA RENIN ACTIVITY
The mean PRA levels at the beginning of the trial fell within the normal range for the laboratory in all patients.
PRA (not corrected for 24-hour sodium excretion7) rose significantly in those patients who received bendrofluazide for eight weeks, but returned to pretreatment levels after treatment had been continued for a further six months. Among the patients who received reserpine plus bendrofluazide no significant increase in the mean PRA could be shown either in the short or long term. The control values in this group were not significantly different from those of the larger group who did not receive reserpine (fig 2) .
Discussion
The results obtained in the random allocation, double-blind, balanced crossover study in mild hypertension were not sig- 
